

# RETHINKING THE TREATMENT OF AKs: ADVANCES IN PHOTODYNAMIC THERAPY

Mark Baldyga – VP Sales, Marketing & Market Access

Samantha Widdicombe – VP Corporate Strategy & Key Accounts

Jon Lyons, PhD, MBA – VP Medical & Scientific Affairs

1

BF\_1411\_ITC\_00038818




# Biofrontera Inc. at a glance

- Founded in 2015, US HQ in Woburn, MA
- Global footprint with Biofrontera AG in Leverkusen, Germany, founded in 2007
- Focus on photodynamic therapy and branded antibiotics
- Successful Biofrontera Inc. IPO in Oct 2021 & poised for growth (Nasdaq: BFRI)



BF\_1411\_ITC\_00038819


# Our global milestones



• INSERT MISSION STATEMENT HERE



BF\_1411\_ITC\_00038820

# We continue to invest in PDT




BF\_1411\_ITC\_00038821

# Why Red Light PDT Matters



BF\_1411\_ITC\_00038822


# RhodoLED® XL




- ✓ **RhodoLED® XL** is a red light-emitting LED lamp used in combination with AMELUZ® for lesion- and field-directed Photodynamic Therapy treatment of mild-to-moderate AKs on the face and scalp
- ✓ Telescoping suspension and spring arm capabilities adds flexibility for patient and lamp head positioning
- ✓ Wheels provide easy mobility with safe locking mechanism

BF\_1411\_ITC\_00038823

# RhodoLED® XL



**5 Panels with 225 LEDs in total (45 LEDs/panel) emit a uniform light**



**Allows for full-face or full-scalp illumination treatment**



## Treating with RhodoLED® XL:

- ✓ 13.5 minutes illumination time
- ✓ 37 J/cm<sup>2</sup> of energy delivery
- ✓ Total illumination area of 9.06 x 11.42 in (23 cm x 29 cm) when all 5 panels are used in curved configuration
- ✓ Treatment distance of 4.9 ± 0.59 in (12.5 cm ± 1.5 cm)

BF\_1411\_ITC\_00038824



**New Ameluz  
formulation  
without Propylene  
Glycol**

- Reduced risk of cutaneous allergy to Propylene Glycol
  - PG was allergen of the year in 2018
- New formulation is bioequivalent to previous formulation
  - No difference in % of active (ALA) or quality of ALA
- New formulation relevant to all orders of Ameluz from early August onward

BF\_1411\_ITC\_00038825

Thank you!